We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Belgian pharmaceutical company UCB SA said Monday it may be interested in Eli Lilly & Co.'s (LLY) research and development center at Mont-Saint-Guibert in Belgium.
Intec Pharma has enlisted two North American dosage form manufacturers to make "supergenerics" using its new method of oral drug delivery that can transform existing drugs into more powerful therapies.
NexMed, Inc., a developer of innovative transdermal treatments based on the NexACT drug delivery technology, today announced that it has received a notice from Nasdaq indicating that it has not regained compliance in accordance with Marketplace Rule 4450(e)(4) as the
market value of its common stock has remained below the minimum of $50,000,000 required for continued inclusion in the Nasdaq National Market.
Endo Pharmaceuticals has reported that the FDA has granted final approval of the company's new drug applications for its extended-release and immediate-release formulations of oxymorphone hydrochloride.
The FDA is rejecting the efforts of some healthcare groups to use head-to-head trials between different drug products as part of new drug applications, arguing that these tests are less efficient or effective than placebo-controlled tests, a high-ranking agency official says.
Dr. Maureen Lindsay, chief executive of Edinburgh-based biotech group Ardana, claimed the last year had been one "significant progress", despite a slight widening of losses.